Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 485

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 485
---
|:--|:-----------------|:--|-----------:|:--|:--|:--|:-----------------|:--|---------:|:--|:--|
| Startup expenses                     | ​ | ​ | ​                | $ |  1,041,535 | ​ | ​ | ​ | ​                | $ |  637,807 | ​ | ​ |
| Accrued Interest                     | ​ | ​ | ​                | ​ |      7,307 | ​ | ​ | ​ | ​                | ​ |        — | ​ | ​ |
| Total deferred tax asset             | ​ | ​ | ​                | ​ |  1,048,842 | ​ | ​ | ​ | ​                | ​ |  637,807 | ​ | ​ |
| Valuation allowance                  | ​ | ​ | ​                | ​ | -1,048,842 | ​ | ​ | ​ | ​                | ​ | -637,807 | ​ | ​ |
| Deferred tax asset, net of allowance | ​ | ​ | ​                | $ |          — | ​ | ​ | ​ | ​                | $ |        — | ​ | ​ |

F-48

TABLE OF CONTENTS

IRIS ACQUISITION CORP NOTES TO FINANCIAL STATEMENTS The income tax provision for the years ended December 31, 2023 and 2022 consists of the following:

| ​                             
 Federal                       | ​ 
 ​ | ​ 
 ​ | December 31,2023 
 ​                | ​ |        ​ | ​ | ​ 
 ​ | ​ 
 ​ | December 31,2022 
 ​                | ​ |        ​ | ​ | ​ 
 ​ |
|:------------------------------|:--|:--|:-----------------|:--|---------:|:--|:--|:--|:-----------------|:--|---------:|:--|:--|
| Current                       | ​ | ​ | ​                | $ |   33,987 | ​ | ​ | ​ | ​                | $ |  539,823 | ​ | ​ |
| Deferred                      | ​ | ​ | ​                | ​ | -411,035 | ​ | ​ | ​ | ​                | ​ | -287,359 | ​ | ​ |
| State                         | ​ | ​ | ​                | ​ |        ​ | ​ | ​ | ​ | ​                | ​ |        ​ | ​ | ​